Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00052195

Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People

DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)

Sponsor: Dartmouth-Hitchcock Medical Center

Interventions SRL-172

Updated 5 times since 2017 Last updated: Feb 17, 2016 Started: Sep 30, 2001 Primary completion: Dec 31, 2008 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on HIV Infections and Tuberculosis, this trial is completed. The trial is conducted by Dartmouth-Hitchcock Medical Center and has accumulated 5 data snapshots since 2001. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dartmouth-Hitchcock Medical Center
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dar es Salaam, Tanzania